secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019083
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA Q1 2023: $351.2M cash, darovasertib 45% ORR in 1L MUM, starting Phase 2/3
--------------------------------------------------------------------------------

- Cash, equivalents & marketable securities $351.2M as of Mar 31, plus $188.7M net from Apr offering, funding into 2027.
- Darovasertib + crizotinib Phase 2: 45% ORR, 90% DCR, ~7 mo median PFS in 1L MUM; 30% ORR any-line MUM.
- Initiating Phase 2/3 registrational trial in 1L HLA-A2(-) MUM in Q2 2023 with median PFS primary endpoint.
- Neoadjuvant darovasertib case: ~80% ocular tumor shrinkage, avoided enucleation, restored 6/5 vision.
- IDE161 first cohort enrolled in Phase 1; Pol Theta Helicase IND targeted Q2 2023 ($7M GSK milestone).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017023019083/0000950170-23-019083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017023019083/idya-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer